Low-intensity Electroporal shock wave-based regenerative therapy for muscular atrophy: Low-intensity Electroporal shock wave therapy increases the expression of IGF-1, PI3K(p85a) and B-Myb, decreases the expression of tumor suppressors, promotes regeneration of muscle cells, and reverses muscle atrophy via up regulation of its target gene, 20/June/2017, 10.35 am

Natural product-derived therapy for Acute Myeloid Leukemia: Theabrownin (TB), isolated from the fresh leaves of Camellia sinensis, decreases the expression of BCLAF1, promotes differentiation of acute myeloid leukemic cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 20/June/2017, 8.15 am
June 20, 2017
The PD-1 pathway activation for Pain therapy: Pyruvate, the end product of glycolysis, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 20/June/2017, 10.51 am
June 20, 2017
Show all

Introduction: What they say

A study from the Cardiac Regeneration and Ageing Lab, School of Life Science, Shanghai University, Shanghai 200444, China shows that “miR-29b contributes to multiple types of muscle atrophy.” This research paper was published, in the 25 May 2017 issue of the journal “Nature communications” [One of the best research journals in Biology with an I.F of 11.329 ], by Prof. Xiao J, Li J and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Low-intensity Electroporal shock wave-based regenerative therapy for muscular atrophy: Low-intensity Electroporal shock wave therapy increases the expression of IGF-1, PI3K(p85a) and B-Myb, decreases the expression of tumor suppressors, promotes regeneration of muscle cells, and reverses muscle atrophy via up regulation of its target gene


From significance of the study to Public health relevance:

Given: (1) that Muscular dystrophy/wasting is a degenerative disease; (2) that Muscular dystrophy/wasting also occur due to a number of pathophysiological conditions, including cancer, denervation, disuse and fasting ; (3) that there is no permanent cure for muscular dystrophy; (4)  the life-long discomfort and the medical care required to alleviate pain-associated (muscle weakness) with muscular dystrophy; and (5) the global economic cost spent for muscular dystrophy is enormous, there is an urgent need to find: (i) a way to rejuvenate muscle (satellite) stem cells that were lost in Muscular dystrophy; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.


What is known?

Prof. Xiao’s research team members has shown that miRNA-29b:(1) promotes skeletal muscle atrophy; and (2) decreases the expression of IGF-1, PI3K(p85a) and B-Myb. While inhibition of MiR-29b expression: (i) stifles atrophy induced by dexamethasone (Dex), TNF-a and H2O2 treatment; (ii) increases phosphorylations of AKT (Ser-473), FOXO3A (Ser-253), mTOR and P70S6K; (iii) decreases expression of Foxo transcription factors; (iv) inhibits ubiquitin ligase expression; (v) suppresses protein degradation; (vi) increases protein synthesis; (vii) augments the expression of myosin isoforms, including Myh7; (vii) stimulates muscle regeneration, growth, and proliferation, suggesting that inhibition of MiR-29b expression in muscles may attenuate muscular dystrophy.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a low-intensity extracorporeal shock wave therapy for Muscular dystrophy.

Low-intensity extracorporeal shock wave therapy, by increasing the expression of its target genes, it may decrease the expression of MiR-29b etc. (Fig. 1). Thereby, it may: (1) increase the expression of IGF-1, PI3K(p85a) and B-Myb; (2) increase phosphorylations of AKT (Ser-473), FOXO3A (Ser-253), mTOR and P70S6K; (3) decrease the expression of Forkhead Box O3 (FOXO3) and its downstream target genes such as MAFBX etc.,; and (4) promote the expression of myosin isoforms, such as Myh7; (vii) augment muscle regeneration, growth, and proliferation.

 

Thus,  by subjecting myocardial patients to Low-intensity extracorporeal shock wave therapy, one may inhibit muscular dystrophy.

Based on this finding, physicians/myologists/orthopaedicians may consider adapting  Low-intensity extracorporeal shock wave therapy (figure 1) in the treatment of muscular dystrophy. [easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how Low-intensity Electroporal shock wave therapy, by decreasing the expression of MiR-29b, may promote regeneration of muscle cells and attenuate muscular dystrophy


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Low-intensity Electroporal shock wave therapy decrease the expression of MiR-29b to re promote regeneration of muscle cells and attenuate muscle dystrophy?
Amount: $ 1, 500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Low-intensity Electroporal shock wave-based regenerative therapy for muscular atrophy: Low-intensity Electroporal shock wave therapy increases the expression of IGF-1, PI3K(p85a) and B-Myb, decreases the expression of tumor suppressors, promotes regeneration of muscle cells, and reverses muscle atrophy via up regulation of its target gene, 20/June/2017, 10.35 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.